Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group

Smith DW , Frankel LR , Mathers LH , Tang ATS , Ariagno RS , and Prober CG : A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. NEJM. 1991; 325:24–29.

Li L , Avery R , Budev M , Mossad S , and Danziger-Isakov L : Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012; 31:839–844.

Hayden FG , Gubareva LV , Monto AS , Klein TC , Elliott MJ , Hammond JM , Sharp SJ , and Ossi MJ : Inhaled zanamivir for the prevention of influenza in families. NEJM. 2000; 343:1282–1289.

Dolovich MB , Ahrens RC , Hess DR , Anderson P , Dhand R , Rau JL , Smaldone GC , Guyatt G , American College of Chest Physicians; and American College of Asthma, Allergy, and Immunology: Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127:335–371.

Cipolla D , and Chan HK : Current and emerging inhaled therapies of repositioned drugs. Adv Drug Deliv Rev. 2018; 133:1–4.

De Castro JF , and Kumate J : Vaccination against measles: The situation in Mexico and America - Advances in the method of aerosol immunization. Bol Med Hosp Infant Mex. 1990; 47:449–461.

Sun D : Remdesivir for treatment of COVID-19: Combination of pulmonary and IV administration may offer additional benefit. AAPS J. 2020; 22:77.

Ari A , Fink JB , and Dhand R : Inhalation therapy in patients receiving mechanical ventilation: An update. J Aerosol Med Pulm Drug Deliv. 2012; 25:319–332.

Li J : Evidence based recommendations on preventing nosocomial transmission for clinicians while taking care of coronavirus infected patients. ISAM Webinar 2020 . https://www.isam.org/covid (accessed May 19, 2020).

Ari A : Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020; 167:105987.

Fink JB , Ehrmann S , Li J , Dailey P , McKiernan P , Darquenne C , Martin AR , Rothen-Rutishauser B , Kuehl PJ , Haeussermann S , MacLoughlin R , Smaldone GC , Mullinger B , Corcoran TE , and Dhand R : Reducing Aerosol-related risk of transmission in the era of COVID-19 . A guidance endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020 (Submitted).

Laube B, Janssens HM, de Jongh HC, Devadason SG, Dhand R Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, and Chrystyn H: ERS/ISAM task force consensus statement: What the pulmonary specialist should know about the new inhalation therapies.Eur Respir J 2011;37:1308–1331.

Landray M : Designing high-quality COVID-19 treatment trials: Clinical Trials Transformation Initiative . 2020. https://www.ctti-clinicaltrials.org/briefing-room/webinars/designing-high-quality-covid-19-treatment-trials (accessed May 12, 2020).

US Department of Health and Human Services: HIV/AIDS News: FDA grants accelerated approval for 3TC with AZT to treat AIDS . Nov 20, 1995. https://aidsinfo.nih.gov/news/203/fda-grants-accelerated-approval-for-3tc-with-azt-to-treat-aids (accessed May 11, 2020).

Gilead Sciences Inc. , Press Release—Oct 26 , 2001. U.S. FDA Approves Gilead Sciences' Anti-HIV Drug Viread™ . https://www.gilead.com/news-and-press/press-room/press-releases/2001/10/us-fda-approves-gilead-sciences-antihiv-drug-viread (accessed May 11, 2020).

US Food and Drug Administration: Guidance for industry. Expedited programs for serious conditions—Drugs and biologics. 2014. https://www.fda.gov/media/86377/download (accessed May 11, 2020).

US Food and Drug Administration: Guidance for Industry and Investigators. Covid-19 public health emergency: General considerations for pre-IND meeting requests for Covid-19 related drugs and biological products. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related (accessed May 15, 2020).

Hassoun M , Malmlöf M , Scheibelhofer O , Kumar A , Bansal S , Selg E , Nowenwik M , Gerde P , Radivojev S , Paudel M , Arora S , and Forbes B : Use of PBPK modeling to evaluate the performance of DissolvIt, a biorelevant dissolution assay for orally inhaled drug products. Mol Pharmaceutics. 2019; 16:1245–1254.

US Food and Drug Administration: Guidance for Industry. Determining whether to submit an ANDA or a 505(b)(2) application. 2019. https://www.fda.gov/media/124848/download (accessed May 11, 2020).

Lewallen S , and Courtright P : Epidemiology in practice: Case-control studies. Community Eye Health. 1998; 11:57–58. https://himmelfarb.gwu.edu/tutorials/studydesign101/casecontrols.cfm

Tavernier E , Trinquart L , and Giraudeau B : Finding alternatives to the dogma of power-based sample size calculation: Is a fixed sample size prospective meta-experiment a potential alternative?. PLoS One. 2016; 11:e0158604.